# A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

> **NCT06037252** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 414 (actual)

## Conditions studied

- Type 2 Diabetes
- Obesity

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06037252
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2026-01-08
- **Final completion:** 2026-10
- **Target enrollment:** 414 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06037252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06037252, "A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06037252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*